Apimeds Pharmaceuticals US Inc
APUS | AMEX
$2.94
-$0.06 (-2.16%)
Nov 2, 2026, 10:30 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 20.04K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -20.04K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -6.28M | -4.07M | -7.04M | -1.84M | -2.66M | -364.37K | -275.61K | -300K | -427.76K | -271.73K | -559.07K | -104.16K | -27.83K | -56.38K | -66.19K |
Interest Income | 21.76K | 7 | 35.92K | 56.43K | 15.25K | 3 | 30 | 116 | 517 | 2.16K | 5.58K | 2.23K | n/a | n/a | n/a |
Pretax Income | -20.17M | -35.06M | -1.16M | -1.78M | -2.66M | -402.4K | -311.63K | -332.52K | -449.36K | -296.47K | -566.97K | -110.02K | -36.08K | -64.63K | -74.59K |
Net Income | -20.17M | -35.06M | -1.16M | -1.78M | -2.66M | -402.4K | -311.63K | -332.52K | -449.36K | -296.47K | -566.97K | -110.02K | -36.08K | -64.63K | -74.59K |
Selling & General & Admin | 5.32M | 11.28M | 6.68M | 1.22M | 2.01M | 364.37K | 275.61K | 300K | 427.76K | 271.73K | 530.52K | 107.16K | 5.39K | 5.83K | 4.07K |
Research & Development | 959.74K | 901.14K | 361.1K | 619.69K | 651.78K | n/a | n/a | n/a | n/a | n/a | 28.55K | -3K | 22.44K | 50.55K | 62.12K |
Other Expenses | n/a | -8.13M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 6.28M | 4.05M | 7.04M | 1.84M | 2.66M | 364.37K | 275.61K | 300K | 427.76K | 271.73K | 559.07K | 104.16K | 27.83K | 56.38K | 66.19K |
Interest Expense | 3.22M | 859.41K | 215.62K | 6.3K | 23.05K | 38.03K | 36.05K | 32.64K | 22.12K | 26.91K | 13.48K | 8.09K | 8.25K | 8.25K | 8.41K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 6.28M | 4.07M | 7.04M | 1.84M | 2.66M | 364.37K | 275.61K | 300K | 427.76K | 271.73K | 559.07K | 104.16K | 27.83K | 56.38K | 66.19K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.63M | 1.55M | 1.09M | 125.76K | 103.69K | 115.72K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K |
Shares Outstanding (Diluted) | 1.63M | 1.55M | 1.09M | 125.76K | 103.69K | 115.72K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K |
EPS (Basic) | -11.77 | -22.60 | -0.92 | -14 | -26 | -3.48 | -2.70 | -2.88 | -3.90 | -2.57 | -4.92 | -0.95 | -0.31 | -0.56 | -0.65 |
EPS (Diluted) | -11.77 | -22.60 | -0.92 | -14 | -26 | -3.48 | -2.46 | -2.62 | -3.54 | -2.34 | -4.47 | -0.87 | -0.28 | -0.51 | -0.59 |
EBITDA | -16.93M | -34.18M | -935.68K | -1.77M | -2.64M | -364.37K | -275.58K | -299.88K | -427.24K | -269.57K | -553.49K | -101.93K | -27.83K | -56.38K | -66.19K |
EBIT | -16.95M | -34.2M | -939.67K | -1.77M | -2.64M | -364.37K | -275.58K | -299.88K | -427.24K | -269.57K | -553.49K | -101.93K | -27.83K | -56.38K | -66.19K |
Depreciation & Amortization | 20.28K | 20.04K | 3.99K | 1.49K | 232 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove APUS